Xinyi W. Zhang

12 East Wenhui Road
Yangzhou, 225009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Hotspots and research trends of exercise in polycystic ovary syndrome: a bibliometric analysis from 2005 to 2025.

Hotspots and research trends of exercise in polycystic ovary syndrome: a bibliometric analysis from 2005 to 2025.

Journal: Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology

Published: July 09, 2026

Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: an 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based study.

Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: an 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based study.

Journal: Journal of gastrointestinal oncology

Published: April 01, 2026

A reducing substances response ratio fluorescence system based on MnO2/MOF for the determination and distinction of organophosphorus pesticides and reducing biological molecules.

A reducing substances response ratio fluorescence system based on MnO2/MOF for the determination and distinction of organophosphorus pesticides and reducing biological molecules.

Journal: Analytica chimica acta

Published: January 21, 2026

GPC6 facilitates progression of SHH-subgroup medulloblastoma by enhancing Hedgehog secretion and signaling responses.

GPC6 facilitates progression of SHH-subgroup medulloblastoma by enhancing Hedgehog secretion and signaling responses.

Journal: Journal of biomedical research

Published: November 30, 2025

DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer.

DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer.

Journal: Journal of gastrointestinal oncology

Published: November 20, 2025

CMA-mediated USP9X degradation promotes SHH medulloblastoma progression by facilitating SUFU ubiquitination.

CMA-mediated USP9X degradation promotes SHH medulloblastoma progression by facilitating SUFU ubiquitination.

Journal: Clinical and translational medicine

Published: October 30, 2025

A novel macrophage membrane-camouflaged ultra-small copper sulfide and photothermal-responsive nitric oxide donor nanocomposites for enhanced synergistic antitumor therapy.

A novel macrophage membrane-camouflaged ultra-small copper sulfide and photothermal-responsive nitric oxide donor nanocomposites for enhanced synergistic antitumor therapy.

Journal: Colloids and surfaces. B, Biointerfaces

Published: October 20, 2025

Important role of OATP in the liver disposition of ezetimibe and its consequent glucuronidation metabolite.

Important role of OATP in the liver disposition of ezetimibe and its consequent glucuronidation metabolite.

Journal: Drug metabolism and pharmacokinetics

Published: April 06, 2025

Mendelian Randomization Analyses Reveal Causal Relationships between Brain Structural Connectivity and Risk of Polycystic Ovary Syndrome.

Mendelian Randomization Analyses Reveal Causal Relationships between Brain Structural Connectivity and Risk of Polycystic Ovary Syndrome.

Journal: Gynecologic and obstetric investigation

Published: March 12, 2025

Plasma proteomic biomarkers predict therapeutic responses in advanced biliary tract cancer patients receiving Camrelizumab plus the GEMOX treatment.

Plasma proteomic biomarkers predict therapeutic responses in advanced biliary tract cancer patients receiving Camrelizumab plus the GEMOX treatment.

Journal: NPJ precision oncology

Published: October 26, 2024

Molecular characterization of FGFR fusion in a large real-world population and clinical utility of bidirectional fusion.

Molecular characterization of FGFR fusion in a large real-world population and clinical utility of bidirectional fusion.

Journal: Chinese medical journal

Published: August 09, 2024

Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers.

Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers.

Journal: Cancer science

Published: July 18, 2024

Showing 1-12 of 39

Last Updated: 09/26/2026